

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

Last Update: Jun 29, 2025

A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis

ClinicalTrials.gov Identifier:

[NCT06655896](#)

Novartis Reference Number:CYTB323K12201

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab. This is a phase 2, multi-part, five-year, randomized, open-label, assessor-blinded, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab in participants with severe refractory diffuse cutaneous systemic sclerosis (dcSSc). This study comprises two cohorts:

- * A Lead-in Cohort enrolling participants to receive rapcabtagene autoleucel.
- * A Randomized Cohort enrolling participants to receive rapcabtagene autoleucel or rituximab. Participants in the rituximab arm whose disease is not fully controlled may receive rapcabtagene autoleucel treatment once the participant is confirmed to be eligible per protocol.

After end of study, participants who received rapcabtagene autoleucel infusion will enter a long-term follow-up (LTFU) period after rapcabtagene autoleucel infusion. This LTFU will be described in a separate study protocol.

Condition

Scleroderma, Diffuse

Phase

Phase2

Overall Status

Recruiting

Number of Participants

86

Start Date

Oct 29, 2024

Completion Date
Oct 13, 2032
Gender
All
Age(s)
18 Years - 65 Years (Adult, Older Adult)

Interventions

Biological

rapcabtagene autoleucel

single infusion of rapcabtagene autoleucel
Biological

rituximab

rituximab intravenous infusion (i.v.) as per protocol

Eligibility Criteria

Inclusion Criteria:

1. Participant must fulfill the 2013 American College of Rheumatology/ European League Against Rheumatism classification criteria for systemic sclerosis and meet the diffuse cutaneous SSc (dcSSc) subset classification according to LeRoy.
2. Disease onset from the first non-Raynaud symptoms attributable to SSc (e.g., puffy hands, scleroderma, digital ulcers, arthralgia, dyspnea) within 7 years prior to the Screening visit.
3. Severe, progressive systemic sclerosis disease defined by at least one of the following:
 - * Progressive systemic sclerosis-associated interstitial lung disease
 - * Severe, progressive systemic sclerosis skin disease
 - * Clinically significant systemic sclerosis-associated cardiac involvement at Screening

Exclusion Criteria:

1. Any condition during Screening that could prevent a complete washout of medications as required per protocol or could otherwise make the participant ineligible for anti-CD19 CAR-T therapy and further participation in the study, as judged by the Investigator.
2. Participants with history of hypersensitivity to excipients in rapcabtagene autoleucel or to rituximab.
3. Any participant for whom treatment with rituximab is clinically inappropriate in the opinion of the investigator.
4. Any medical conditions that are not related to SSc that, in the opinion of the Investigator, would jeopardize the ability of the participant to tolerate lymphodepletion and anti-CD19 CAR-T cell therapy.
5. Rheumatic disease other than dcSSc, (except secondary Sjogren's syndrome or scleroderma myopathy), including limited cutaneous systemic sclerosis (lcSSc) or sine scleroderma at Screening.
6. Participants with pre-existing pulmonary hypertension.
7. Significant renal pathology at Screening.
8. Participants with uncontrolled stage II hypertension at Screening.
9. Vaccination with live attenuated vaccines within 6 weeks prior to randomization.

Other protocol-defined inclusion/exclusion criteria may apply.

Australia

Novartis Investigative Site

Recruiting

Darlinghurst, New South Wales, 2010, Australia

France

Novartis Investigative Site

Recruiting

Rennes, 35000, France

Novartis Investigative Site

Recruiting

Dijon, 21034, France

Novartis Investigative Site

Recruiting

Bordeaux Cedex, 33076, France

Novartis Investigative Site

Recruiting

Montpellier, 34295, France

Germany

Novartis Investigative Site

Recruiting

Leipzig, Sachsen, 04103, Germany

Novartis Investigative Site

Recruiting

Berlin, 13353, Germany

Novartis Investigative Site

Recruiting

Jena,07740,Germany

Israel

Novartis Investigative Site

Recruiting

Haifa,3109601,Israel

Novartis Investigative Site

Recruiting

Tel Aviv,6423906,Israel

Novartis Investigative Site

Recruiting

Ramat Gan,5265601,Israel

Italy

Novartis Investigative Site

Recruiting

Udine,UD,33100,Italy

Novartis Investigative Site

Recruiting

Ancona,AN,60126,Italy

Novartis Investigative Site

Recruiting

Roma,RM,00168,Italy

Novartis Investigative Site

Recruiting

Genova,GE,16132,Italy

Novartis Investigative Site

Recruiting

Bergamo,BG,24127,Italy

Novartis Investigative Site

Recruiting

Milano,MI,20132,Italy

Novartis Investigative Site

Recruiting

Brescia,BS,25123,Italy

Novartis Investigative Site

Recruiting

Perugia,PG,06129,Italy

Novartis Investigative Site

Recruiting

Pisa,PI,56124,Italy

Novartis Investigative Site

Recruiting

Pavia,PV,27100,Italy

Novartis Investigative Site

Recruiting

Milano,MI,20122,Italy

Japan

Novartis Investigative Site

Recruiting

Suita,Osaka,565 0871,Japan

Novartis Investigative Site

Recruiting

Kyoto,606 8507,Japan

Novartis Investigative Site

Recruiting

Sapporo city,Hokkaido,060 8648,Japan

Novartis Investigative Site

Recruiting

Kanazawa,Ishikawa,920 8641,Japan

Novartis Investigative Site

Recruiting

Sendai city,Miyagi,980 8574,Japan

Netherlands

Novartis Investigative Site

Recruiting

Utrecht,3584,Netherlands

Singapore

Novartis Investigative Site

Recruiting

Singapore,169608,Singapore

Spain

Novartis Investigative Site

Recruiting

Cordoba,Andalucia,14004,Spain

Novartis Investigative Site

Recruiting

Barcelona,Catalunya,08035,Spain

Novartis Investigative Site

Recruiting

Pamplona,Navarra,31008,Spain

Novartis Investigative Site

Recruiting

Madrid,28041,Spain

Novartis Investigative Site

Recruiting

Barcelona,08041,Spain

Switzerland

Novartis Investigative Site

Recruiting

Geneve 14,1211,Switzerland

Novartis Investigative Site

Recruiting

Lausanne,1011,Switzerland

Taiwan

Novartis Investigative Site

Recruiting

Taichung,407219,Taiwan

United Kingdom

Novartis Investigative Site

Recruiting

Sheffield,South Yorkshire,S10 2jf,United Kingdom

United States

Northwestern University

Recruiting

Chicago,Illinois,60611,United States

George Georges

Federica Sidoti

Email: Federica.sidoti@nm.org

Michigan Med University of Michigan

Recruiting

Ann Arbor, Michigan, 48109 5271, United States

Evelyn Shea

Phone: [734-615-4762](tel:734-615-4762)

Email: shevelyn@med.umich.edu

Monalisa Ghosh

University Of Iowa

Recruiting

Iowa City, Iowa, 52242, United States

Ashley Pieper

Phone: [319-356-2197](tel:319-356-2197)

Email: ashley-pieper@uiowa.edu

Hanna Zembruska

Avera Cancer

Recruiting

Sioux Falls, South Dakota, 57105, United States

Brennan Moran

Phone: [605-322-3296](tel:605-322-3296)

Email: brennan.moran@avera.org

Xavier Andrade-Gonzalez

UCSF

Recruiting

San Francisco, California, 94115, United States

Emily Von Scheven

Zilan Zheng

Phone: [415-353-1301](tel:415-353-1301)

Email: Zilan.Zheng@ucsf.edu

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: [+41613241111](tel:+41613241111)

Email: novartis.email@novartis.com

Novartis Pharmaceuticals

Phone: [1-888-669-6682](tel:1-888-669-6682)

Email: novartis.email@novartis.com

Source URL: <https://prod1.novartis.com/clinicaltrials/study/nct06655896>

List of links present in page

1. <https://clinicaltrials.gov/ct2/show/NCT06655896>
2. [#trial-eligibility](#)
3. <mailto:Federica.sidoti@nm.org>
4. <tel:734-615-4762>
5. <mailto:shevelyn@med.umich.edu>
6. <tel:319-356-2197>
7. <mailto:ashley-pieper@uiowa.edu>
8. <tel:605-322-3296>
9. <mailto:brennan.moran@avera.org>
10. <tel:415-353-1301>
11. <mailto:Zilan.Zheng@ucsf.edu>
12. <tel:+41613241111>
13. <mailto:novartis.email@novartis.com>
14. <tel:1-888-669-6682>
15. <mailto:novartis.email@novartis.com>